References

  1. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR. 2006;55(RR17):1–33.
  2. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention: new opportunities through adult vaccination. Am J Prev Med. 2007;32(3):177–185.
  3. Centers for Disease Control and Prevention. Vaccination coverage among U.S. adults: National Immunization Survey–Adult, 2007. http://www.cdc.gov/vaccines/stats-surv/nis/downloads/nis-adult-summer-2007.pdf. Accessed December 12, 2008.
  4. Brooks DA, Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med. 2006;19(6):603-611.
  5. Gregory DS. Pertussis: a disease affecting all ages. Am Fam Physician. 2006;74(3):420-426.
  6. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39(11):1572-1580.
  7. Pichichero ME, Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med. 1997;151(1):35–40.
  8. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR3): 1–43.
  9. Prescribing Information for BOOSTRIX.
  10. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084-1093.
  11. Centers for Disease Control and Prevention. National Vaccination Coverage Among Adolescents Aged 13–17 Years—United States, 2006. MMWR. 2007;56(34):885–888.
  12. Centers for Disease Control and Prevention. National Vaccination Coverage Among Adolescents Aged 13–17 Years—United States, 2006. Editorial Comment. MMWR. 2007;56(34):885–888.
  13. Centers for Disease Control and Prevention. School-associated pertussis outbreak-Yavapai County, Arizona, September 2002-February 2003. MMWR. 2004;53(10):216-219.
  14. Sotir MJ, Cappozzo DL, Warshauer DM, et al. A countywide outbreak of pertussis: initial transmission in a high school weight room with subsequent substantial impact on adolescents and adults. Arch Pediatr Adolesc Med. 2008;162(1):79-85.

Indication

BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single dose in individuals 10 through 64 years of age.

Important Safety Information

  • In clinical studies, common adverse events were injection-site reactions (pain, redness, swelling, or increase in arm circumference), headache, fatigue, and gastrointestinal symptoms.
  • Severe allergic reaction after a previous dose of BOOSTRIX or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.
  • The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine, or if progressive or unstable neurologic disorders exist.
  • Persons who experienced an Arthus-type hypersensitivity reaction following a previous dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed.
  • The prefilled syringes contain dry natural latex rubber that may cause allergic reactions.

Please see complete Prescribing Information for BOOSTRIX